Homepage Top Section2

CAL101 is intended for the treatment of idiopathic pulmonary fibrosis (IPF). It is currently studied in the Phase II AURORA trial, with patient recruitment underway in the US,

This topical, steroid-free formulation is applied once daily and can be used for long-term disease control without limits on duration or body surface area. Clinical trials have shown

The agreement covers Samsung Bioepis’ two ophthalmology assets, Byooviz (ranibizumab) and Opuviz (aflibercept), in Europe. The transfer returns commercial rights for Byooviz to Samsung Bioepis and positions the

This tripartite agreement leverages expertise in cell immunotherapies, peptide HLA (pHLA) binder discovery, and bispecific T cell engagers, with the aim of overcoming challenges to achieving durable cancer

The deal advances Biogen’s immunology strategy, focussing on established immune mechanisms that may address inflammatory disorders with considerable unmet need. Biogen’s early-stage immunology pipeline is bolstered by the

The focus of this partnership is to create a new vaccine utilising a non-replicating highly attenuated vaccinia virus, designed to enhance safety and reduce the risk of emergence

This comes just two weeks after its US Food and Drug Administration (FDA) approval. The approval is based on results from FIBRONEER-IPF, a Phase III trial in IPF

Under this agreement, McKesson will act as an authorised distributor for the immunotherapy that has received approval from the US Food and Drug Administration (FDA) to treat adults

This partnership will utilise Tempus’ de-identified multimodal database to guide the design of clinical trials. Under the multi-year agreement, Whitehawk will utilise Tempus’ real-world dataset to focus on